Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.
Temming
K
K
Department of Pharmacokinetics and Drug Delivery, Groningen University Institute of Drug Exploration, Antonius Deusinglaan 1, Groningen, The Netherlands. k.temming@rug.nl <k.temming@rug.nl>
Lacombe
M
M
Moorlag
H E
HE
Asgeirsdottir
S A
SA
Orfi
L
L
Kéri
G
G
Poelstra
K
K
Molema
G
G
Kok
R J
RJ
D000418:Albumins / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001667:Binding, Competitive; D002478:Cells, Cultured; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D010793:Phthalazines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011725:Pyridines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000418:Albumins; D004337:Drug Carriers; D009842:Oligopeptides; D010793:Phthalazines; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; C404768:vatalanib; C047981:arginyl-glycyl-aspartic acid